PE20030930A1 - Derivados de tiazol como antagonistas del receptor npy - Google Patents

Derivados de tiazol como antagonistas del receptor npy

Info

Publication number
PE20030930A1
PE20030930A1 PE2003000182A PE2003000182A PE20030930A1 PE 20030930 A1 PE20030930 A1 PE 20030930A1 PE 2003000182 A PE2003000182 A PE 2003000182A PE 2003000182 A PE2003000182 A PE 2003000182A PE 20030930 A1 PE20030930 A1 PE 20030930A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
methyl
antagonists
thazol
Prior art date
Application number
PE2003000182A
Other languages
English (en)
Inventor
Patrizio Mattei
Werner Neidhart
Sven Taylor
Philippe Pflieger
Matthias Heinrich Nettekoven
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20030930A1 publication Critical patent/PE20030930A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

SE REFIERE A DERIVADOS DE TIAZOL DE FORMULA I DONDE R1 ES ARILO, HETEROARILO; R2 ES H, ALQUILO, CICLOALQUILO; R3 ES H, ALQUILO, CICLOALQUILO; R4 ES H, ALQUILO, CICLOALQUILO; R5 ES ALQUILO, CICLOALQUILO, ARILO, HETEROARILO; R6 ES H, ALQUILO, CICLOALQUILO; A ES -C(O)-, -S(O)2, -N(R6)-C(O)-, ENTRE OTROS. SON COMPUESTOS PREFERIDOS {3-[5-(2-METIL-BENZOIL)-TIAZOL-2-ILAMINO]-PROPIL}-AMIDA DEL ACIDO TIOFENO-2-SULFONICO, 2-METOXI-5-METIL-N-{3-[5-(2-METIL-BENZOIL)-TIAZOL-2-ILAMINO]-PROPIL}-BENCENOSULFONAMIDA, 2-CLORO-N-{3-[5-(2-METIL-BENZOIL)-TIAZOL-2-ILAMINO]-PROPIL}-5-TRIFLUOROMETIL-BENCENOSULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON ANTAGONISTAS DEL RECEPTOR DE NEUROPEPTIDO Y (NPY) Y SON UTILES PARA EL TRATAMIENTO DE ARTRITIS, ENFERMEDADES CARDIOVASCULARES, DIABETES
PE2003000182A 2002-02-28 2003-02-25 Derivados de tiazol como antagonistas del receptor npy PE20030930A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004296 2002-02-28

Publications (1)

Publication Number Publication Date
PE20030930A1 true PE20030930A1 (es) 2003-11-08

Family

ID=27763338

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000182A PE20030930A1 (es) 2002-02-28 2003-02-25 Derivados de tiazol como antagonistas del receptor npy

Country Status (21)

Country Link
US (1) US6686381B2 (es)
EP (1) EP1480976B1 (es)
JP (1) JP2005526732A (es)
KR (1) KR100611854B1 (es)
CN (1) CN100363362C (es)
AR (1) AR038704A1 (es)
AT (1) ATE373654T1 (es)
AU (1) AU2003210305B2 (es)
BR (1) BR0308108A (es)
CA (1) CA2475299A1 (es)
DE (1) DE60316411T2 (es)
ES (1) ES2292992T3 (es)
GT (1) GT200300045A (es)
MX (1) MXPA04008379A (es)
PA (1) PA8567301A1 (es)
PE (1) PE20030930A1 (es)
PL (1) PL372463A1 (es)
RU (1) RU2004129285A (es)
TW (1) TW200403995A (es)
UY (1) UY27689A1 (es)
WO (1) WO2003072577A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
JP2007501824A (ja) 2003-08-12 2007-02-01 エフ．ホフマン−ラ　ロシュ　アーゲー Ｎｐｙアンタゴニストとしてのチアゾール誘導体
AU2004263311A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag 2-amino-5-benzoylthiazole NPY antagonists
ATE384058T1 (de) * 2003-12-08 2008-02-15 Hoffmann La Roche Thiazolderivate
EP1753735A1 (en) * 2004-04-20 2007-02-21 Transtech Pharma, Inc. Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
CA2636077C (en) * 2006-01-18 2012-01-03 Amgen Inc. Thiazole compounds as protein kinase b (pkb) inhibitors
WO2010098298A1 (ja) * 2009-02-27 2010-09-02 塩野義製薬株式会社 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
RS65058B1 (sr) 2019-12-30 2024-02-29 Deciphera Pharmaceuticals Llc Formulacije inhibitora amorfne kinaze i postupci njihove primene
BR112022013169A2 (pt) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AUPN163795A0 (en) 1995-03-10 1995-04-06 DIPNALL, David A device for extracting energy from moving water particles
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
TR200100472T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
US20010039275A1 (en) * 2000-02-04 2001-11-08 Bowler Andrew Neil Use of 2,4-diaminothiazole derivatives
AU2001246494A1 (en) * 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
EP1417188A1 (en) * 2001-08-03 2004-05-12 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives

Also Published As

Publication number Publication date
US6686381B2 (en) 2004-02-03
AR038704A1 (es) 2005-01-26
RU2004129285A (ru) 2005-10-27
CN100363362C (zh) 2008-01-23
KR100611854B1 (ko) 2006-08-11
US20030225141A1 (en) 2003-12-04
CA2475299A1 (en) 2003-09-04
WO2003072577A1 (en) 2003-09-04
AU2003210305A1 (en) 2003-09-09
ATE373654T1 (de) 2007-10-15
DE60316411T2 (de) 2008-06-12
TW200403995A (en) 2004-03-16
EP1480976A1 (en) 2004-12-01
PL372463A1 (en) 2005-07-25
KR20040094735A (ko) 2004-11-10
ES2292992T3 (es) 2008-03-16
MXPA04008379A (es) 2004-11-26
CN1639158A (zh) 2005-07-13
UY27689A1 (es) 2003-08-29
EP1480976B1 (en) 2007-09-19
DE60316411D1 (de) 2007-10-31
BR0308108A (pt) 2004-12-07
JP2005526732A (ja) 2005-09-08
GT200300045A (es) 2003-09-23
AU2003210305B2 (en) 2006-07-06
PA8567301A1 (es) 2004-02-07

Similar Documents

Publication Publication Date Title
PE20030930A1 (es) Derivados de tiazol como antagonistas del receptor npy
PE20050121A1 (es) Acidos tienil-hidroxamicos, sustituidos referidos a la actividad enzimatica de la histona desacetilasa
PE20051159A1 (es) Derivados de heteroarilaminopirazol como estimulantes de la produccion de insulina
TWI444378B (zh) 具有β－分泌酶抑制作用之含硫雜環衍生物及其用途
ES2524045T3 (es) Nuevas amidas y tioamidas heteroaromáticas como plaguicidas
KR100561988B1 (ko) 신규 화합물
EP0316723B1 (en) 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
AU2631401A (en) Novel compounds and compositions as protease inhibitors
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
SE456581B (sv) Mellanprodukter for framstellning av 3,4-disubstituerade 1,2,5-tiadiazol-1-oxider och -1,1-dioxider som er h 71-receptorantagonister
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20060727A1 (es) Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
NZ582555A (en) Sulfonamides as trpm8 modulators
KR20090110851A (ko) 키나제 저해제로서 2-아미노티아졸 화합물의 합성 공정
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PT2248809E (pt) (3-[2-(benzo[b]tiofen-5-il)-etoxi]-propanoatos de alquilo a título de intermediários na produção de derivados de azetidin-3-ol
PE20120764A1 (es) Derivados de isotiazolo-pirimidindiona como moduladores de trpa1
PE20040190A1 (es) Tiazoles y oxazoles sustituidos que modulan la actividad de ppar
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
KR20080003380A (ko) 우레아 유도체들, 그 제조방법 및 그 이용
PE20061446A1 (es) Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4
PE20021158A1 (es) Derivados de sulfonamida como antagonistas del receptor de bradiquinina
PE20020603A1 (es) Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)
US20040127426A1 (en) Peptidic compounds as cysteine protease inhibitors

Legal Events

Date Code Title Description
FD Application declared void or lapsed